Clinical trial · Observational
H. Pylori Screen-and-treat Study in a Population of Young Adults
Multicentric Transnational H. Pylori Screen-and-treat Study in a Population of Young Adults
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Gastric cancer remains a major challenge to public health on a global scale. H. pylori related cancer burden contributes to the largest proportion of cancer cases attributable to infections in Europe. Considering its absolute burden and persisting disparities, in addition to the substantial prevalence of H. pylori infection worldwide that is treatable, gastric cancer is a logical target for urgent action for prevention. Population-based H. pylori test-and-treat has therefore been proposed as a strategy for gastric cancer prevention. To fill the gaps in knowledge about gastric cancer prevention through H. pylori screening and eradication in younger adults, a study of a population-based H. pylori test-and-treat strategy in Ireland, Croatia, Latvia, Poland, Romania and Slovenia. Main goals of this study are to assess future program processes, feasibility, acceptability and effectiveness. In total of 6,800 adults aged 30-34 will be tested for H. pylori infection. They will be randomly selected to represent the chosen population and invited to participate in the study based on informed consent. Confirmed infections will be treated by available combined therapy in line with treatment guidelines and the success of eradication will be retested during a control check-up. Patients who will provide their consent to participate will undertake an interview about the risk factors in early childhood and their habits regarding alcohol consumption and use of tobacco. Compliance to testing and treatment, treatment results, adverse effects and reasons for dropping out will be additionally monitored. Gathered data will be analysed in alignment with our research questions. The investigators will disseminate reports and present the results to both the general public and the scientific community in order to foster future developments in gastric cancer prevention.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| H-pylori | — | UNRESOLVED | — |
| H Pylori Eradication | — | UNRESOLVED | — |
| H Pylori Infection | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bismuth-based quadruple therapy | Drug | — | UNRESOLVED |
| Levofloxacin-based quadruple therapy | Drug | — | UNRESOLVED |
| Levofloxacin-based triple | Drug | — | UNRESOLVED |
| Standard triple therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Protocol I
- description
- H. pylori positive patients who will be treated by bismuth-based quadruple therapy. Participating centers: KBC Rijeka, Croatia; KBC Zagreb, Croatia; Beacon Hospital, Ireland; Uniwersytet medyczny we Wrocławiu, Poland; UMF Cluj-Napoca, Romania; NIJZ, Slovenia
- interventionNames
- Drug: Bismuth-based quadruple therapy
- label
- Protocol II
- description
- In case there will be a treatment failure after bismuth-based quadruple therapy, the remaining patients with a positive infection will be referred to a levofloxacin based quadruple therapy. Participating centers: KBC Rijeka, Croatia; KBC Zagreb, Croatia; Beacon Hospital, Ireland; Uniwersytet medyczny we Wrocławiu, Poland; UMF Cluj-Napoca, Romania; NIJZ, Slovenia
- interventionNames
- Drug: Levofloxacin-based quadruple therapy
- label
- Standard triple therapy
- description
- H. pylori positive participants who will offered standard triple therapy. Participating center: University of Latvia, Latvia
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 34 Years
Show eligibility criteria text
Inclusion Criteria: * Young adults (generally 30 - 34 years of age) Exclusion Criteria: * Patients with mental or developmental limitations who cannot provide a fully-informed consent to participate (based on the assessment from research or patient's personal physician team) * Previously treated H. pylori infection * History of partial or total gastric resection due to benign or malign lesions
References
Publications (0)
Data not yet available